PMID- 37069463
OWN - NLM
STAT- MEDLINE
DCOM- 20230601
LR  - 20230601
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Linking)
VI  - 31
IP  - 3
DP  - 2023 Jun
TI  - Pterostilbene reduces the progression of atopic dermatitis via modulating 
      inflammatory and oxidative stress biomarkers in mice.
PG  - 1289-1303
LID - 10.1007/s10787-023-01214-z [doi]
AB  - Atopic dermatitis (AD) is one of the most prevalent chronic skin inflammatory 
      disorders requiring continuous treatment and care. Pterostilbene (PTN) belongs to 
      stilbene and is a polyphenolic compound of natural origin. It is similar to 
      resveratrol and has analogous anti-inflammatory, anti-oxidant, and 
      anti-carcinogenic characteristics. This study was intended to evaluate the effect 
      of PTN against atopic dermatitis. The disease was induced by sensitization with 
      2,4-dinitrochlorobenzene (DNCB) in mice. The standard control group (SCG) 
      received topical 0.1% tacrolimus (TC), whereas three other treatment groups 
      received daily topical PTN at 0.2, 0.6, and 1% w/w for 28 days. Dermatitis 
      scoring, ear thickness, and body weight of animals were weekly determined while 
      other parameters were assessed at the termination of the experiment. PTN reduced 
      the ear weight, skin thickness, and the weight and size of thymus glands and 
      spleen in comparison with diseased animals. PTN also reduced the elevated 
      immunoglobulin E (IgE) level and blood inflammatory cells in diseased mice. The 
      histopathological findings showed a decreased epidermal thickness in PTN-treated 
      groups. Moreover, treatment with PTN improved the amount of oxidative stress 
      markers in the skin of the diseased mice. The expressions of IL-4, IL-6, TNF-alpha, 
      and NF-kappaB in the skin of diseased mice were also reduced by PTN. This study 
      concludes that PTN ameliorated the symptoms of atopic dermatitis through the 
      reduction of inflammation, oxidative damage, and inflammatory cytokines in the 
      skin of diseased animals. Therefore, PTN must be further investigated for the 
      treatment of AD complications and other inflammatory skin disorders.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Bangash, Yasmin
AU  - Bangash Y
AD  - Riphah Institute of Pharmaceutical Sciences, Riphah International University, 
      Lahore, Pakistan.
FAU - Saleem, Ammara
AU  - Saleem A
AD  - Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government 
      College University Faisalabad, Faisalabad, Pakistan. ammarasaleem@gcuf.edu.pk.
FAU - Akhtar, Muhammad Furqan
AU  - Akhtar MF
AUID- ORCID: 0000-0003-2270-6242
AD  - Riphah Institute of Pharmaceutical Sciences, Riphah International University, 
      Lahore, Pakistan. furqan.pharmacist@gmail.com.
FAU - Anwar, Fareeha
AU  - Anwar F
AD  - Riphah Institute of Pharmaceutical Sciences, Riphah International University, 
      Lahore, Pakistan.
FAU - Akhtar, Bushra
AU  - Akhtar B
AD  - Department of Pharmacy, University of Agriculture, Faisalabad, Pakistan.
FAU - Sharif, Ali
AU  - Sharif A
AD  - Faculty of Pharmaceutical and Allied Health Sciences, Institute of Pharmacy, 
      Lahore College for Women University, Lahore, Pakistan.
FAU - Khan, Muhammad Imran
AU  - Khan MI
AD  - Riphah Institute of Pharmaceutical Sciences, Riphah International University, 
      Lahore, Pakistan.
FAU - Khan, Aslam
AU  - Khan A
AD  - Riphah Institute of Pharmaceutical Sciences, Riphah International University, 
      Lahore, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20230417
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 26R60S6A5I (pterostilbene)
RN  - 0 (Stilbenes)
RN  - 0 (Cytokines)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Dermatitis, Atopic/drug therapy
MH  - Skin
MH  - *Stilbenes/pharmacology
MH  - Cytokines/metabolism
MH  - Oxidative Stress
MH  - Mice, Inbred BALB C
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - Cytokines
OT  - Inflammation
OT  - Oxidative stress
OT  - Pterostilbene
EDAT- 2023/04/18 06:00
MHDA- 2023/06/01 06:42
CRDT- 2023/04/17 23:31
PHST- 2023/02/23 00:00 [received]
PHST- 2023/03/27 00:00 [accepted]
PHST- 2023/06/01 06:42 [medline]
PHST- 2023/04/18 06:00 [pubmed]
PHST- 2023/04/17 23:31 [entrez]
AID - 10.1007/s10787-023-01214-z [pii]
AID - 10.1007/s10787-023-01214-z [doi]
PST - ppublish
SO  - Inflammopharmacology. 2023 Jun;31(3):1289-1303. doi: 10.1007/s10787-023-01214-z. 
      Epub 2023 Apr 17.